Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Silexion Therapeutics Corp. SLXN stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.

Overall, the updated analysis reveals a 56% objective response rate (ORR) in patients treated with LODER, with the ORR increasing to 67% in patients whose previously non-resectable tumors became resectable.

Silexion had previously reported that patients treated with LODER combined with standard-of-care (SoC) chemotherapy experienced a 9.3-month improvement in overall survival (OS) compared to chemotherapy alone.

The new data now underscores LODERs additional potential to increase the resectability of tumors, opening up more surgical options for patients with otherwise inoperable pancreatic cancer.

Silexion is also progressing with the development of its next-generation product, SIL-204, which builds upon the efficacy of the LODER.

SIL-204 is designed to target a broader range of KRAS mutations.

In August, Silexion Therapeutics and Moringa Acquisition Corp, a publicly-traded special purpose acquisition company, combined with Biomotion Sciences.

The combined company’s name changed from Biomotion Sciences to Silexion Therapeutics.

Price Action: SLXN stock is up 18.3% at $0.91 during the premarket session at last check Tuesday, according to Benzinga Pro.

Read Next:

• T-Mobile To Raise $2.5B Via Debt For Buybacks and Growth.